Advances in cell therapy for renal failure

Transplant Immunology

Volumn 12, Issue 3-4, 2004, Pages 219-227

  Humes, H David ^a   Szczypka, Mark S ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Nephros Therapeutics Inc   (United States)

Author keywords

Acute renal failure; Dialysis; Inflammation; Progenitor; Renal assist device

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ARTIFICIAL KIDNEY; HEMODIALYSIS; HEMOFILTRATION; HUMAN; KIDNEY FAILURE; KIDNEY TUBULE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; UREMIA;

EID: 2442475355     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2003.12.015     Document Type: Article

References (66)

1. Gage F.H. Cell therapy. Nature. 392:1998;518-524
2. Dove A. Cell-based therapies go live. Nat Biotechnol. 20:2002;339-343
3. Petit-Zeman S. Regenerative medicine. Nat Biotechnol. 19:2001;201-206
4. Bianco P., Robey P.G. Stem cells in tissue engineering. Nature. 414:2001;118-121
5. Freed C.R., Greene P.E., Breeze R.E., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's Disease. N Engl J Med. 344:2001;710-719
6. Hagège A.A., Carrion C., Menaschè P., et al. Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. Lancet. 361:2003;491-492
7. Watanabe F.D., Mullon C.J., Hewitt W.R., et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg. 225:1997;484-491
8. Humes H.D., Weitzel W.F., Bartlett R.H., Swaniker F.C., Paganini E.P. Renal cell therapy is associated with dynamic and individualized responses in patients with acute renal failure. Blood Purif. 21:2003;64-71
9. Brower V. Human ES cells: can you build a business around them? Nat Biotechnol. 17:1999;139-142
10. Wertz D.C. Embryo and stem cell research in the United States: history and politics. Gene Ther. 9:2002;674-678
11. Terada N., Hamazaki T., Oka M., et al. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature. 416:2002;542-545
12. Wang X., Willenbring H., Akkari Y., et al. Cell fusion is the principal source of bone marrow-derived hepatocytes. Nature. 422:2003;897-901
13. Vassilopoulos G., Wang P.R., Russell D.W. Transplanted bone marrow regenerates liver by cell fusion. Nature. 422:2003;901-904
14. Szczypka MS, Humes HD. Stem cells and the kidney. In: Lanza RP, Blan HM, Melton DA, Moore MAS, Thomas ED, Verfaillie CM, Weissman IL, West MD, (eds). The Handbook of Adult and Fetal Stem Cells, New York Academic Press, Elsevier Science, in press
15. Hacein-Bey-Abina S., von Kalle C., Schmidt M., et al. A serious adverse event after successful gene therapy for X-linked severe combined immuno-deficiency. N Engl J Med. 348:2003;255-256
16. Dunnett S.B., Bjorklund A., Lindvall O. Cell therapy in Parkinson's disease - stop or go? Nat Rev Neurosci. 2:2001;365-369
17. Menachè P., Hagege A.A., Vilquin J.T., et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol. 41:2003;1078-1083
18. Orive G., Hernandez R.M., Gascon A.R., et al. Cell encapsulation: promise and progress. Nat Med. 9:2003;104-107
19. Humes H.D., Buffington D.A., MacKay S.M., Funke A.J., Weitzel W.F. Replacement of renal function in uremic animals with a tissue-engineered kidney. Nat Biotechnol. 1:1999;451-455
20. Fissell W.H., Lou L., Abrishami S., Buffington D.A., Humes H.D. Bioartificial kidney ameliorates gram-negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol. 14:2003;454-461
21. Avgoustiniatos E.S., Colton C.K. Effect of external oxygen mass transfer resistances on viability of immunoisolated tissue. Ann NY Acad Sci. 831:1997;145-167
22. Richardson T.P., Peters M.C., Ennett A.B., Mooney D.J. Polymeric system for dual growth factor delivery. Nat Biotechnol. 19:2001;1029-1034
23. Humes HD. Implantable device and use thereof. US Patent 5, 704, 910, January 6, 1998
24. Excerpts from United Stated Renal Data System: Annual Data Report. Am J Kidney Dis 1998;32:569-580
25. Iglehart J.K. The American health care system: the end stage renal disease program. N Engl J Med. 328:1993;366-371
26. Humes H.D. Acute renal failure: prevailing challenges and prospects for the future. Kidney Int. 48:1995;S26-S32
27. Chertow G.M., Levy E.M., Hammermeister K.E., Grover F., Daley J. Independent association between acute renal and mortality following cardiac surgery. Am J Med. 104:1998;343-348
28. Bates D.W., Su L., Yu D.T., et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 32:2001;686-693
29. Breen D., Bihari D. Acute renal failure as a part of multiple organ failure: the slippery slope of critical illness. Kidney Int. 53:(Suppl 66):1998;S25-S33
30. Humes H.D. Bioartificial kidney for full renal replacement therapy. Semin Nephrol. 20:2000;71-82
31. Bishop G.A., Waugh J.A., Hall B.M. Expression of HLA antigens on renal tubular cell stimulation of lymphocyte activation and on their vulnerability to cell-mediated lysis. Transplantation. 46:1988;303-310
32. Wüthrich R.P., Yui M.A., Mazoujian G., Nabavi N., Glimcher L.H., Kelley V.E. Enhanced MHC class II expression in renal proximal tubules preceded loss of renal function in MRL/lpr mice with lupus nephritis. Am J Pathol. 134:1989;45-51
33. Wüthrich R.P., Glimcher L.H., Yui M.A., Jevnikar A.M., Dumas S.E., Kelley V.E. Generation of highly differentiated murine renal tubular epithelial cell lines: MHC class II regulation, antigen presentation and tumor necrosis factor production. Kidney Int. 37:1990;783-792
34. Wahl P., Schoop R., Bilic G., et al. Renal tubular epithelial expression of the costimulatory molecule B7RP-1(Inducible Costimulator Ligand). J Am Soc Nephrol. 13:2002;1517-1526
35. Boswell R.N., Yard B.A., Schrama E., van Es L.A., Daha M.R., van der Woude F.J. Interleukin 6 production by human proximal tubular epithelial cells in vitro: analysis of the effects of interleukin-1 alpha (IL-1 alpha) and other cytokines. Nephrol Dial Transplant. 9:1994;599-606
36. Leonard M., Ryan M.P., Watson A.J., Schramek H., Healy E. Role of MAP kinase pathway in mediating IL-6 production in human primary mesangial and proximal tubular cells. Kidney Int. 56:1999;1366-1377
37. Yard B.A., Daha M.R., Kooymans-Couthino M., et al. IL-1 alpha stimulated TNF alpha production by cultured human proximal tubular epithelial cells. Kidney Int. 42:1992;383-389
38. van Kooten C., van der Linde X., Woltman A.M., van Es L.A., Daha M.R. Synergistic effect of interleukin-1 and CD40L on the activation of human renal tubular epithelial cells. Kidney Int. 56:1999;41-51
39. Prodjosudjadi W., Gerritsma J.S., Klar-Mohamed N., et al. Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int. 48:1995;1477-1486
40. Kimmel P.L., Phillips T.M., Simmens S.J., et al. Immunologic function and survival in hemodialysis patients. Kidney Int. 54:1998;236-244
41. Bologa R.M., Levine D.M., Parker T.S., et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 32:1998;107-114
42. Zimmermann J., Herrlinger S., Pruy A., Metzger T., Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 55:1999;648-658
43. Himmelfarb J., McMenamin E., McMonagle E. Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int. 61:(2):2002;705-716
44. Himmelfarb J., McMonagle E., McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int. 58:(6):2000;2571-2578
45. Hall P.A., Watt P.M. The generation and maintenance of cellular diversity. Development. 106:1989;619-633
46. Potten C.S., Loeffler M. Stem cell: lessons for and from the crypt. Development. 110:1990;1001-1020
47. Humes H.D., Cieslinski D.A. Interaction between growth factors and retinoic acid in the induction of kidney tubulogenesis. Exp Cell Res. 201:1992;8-15
48. Humes H.D., Krauss J.C., Cieslinski D.A., Funke A.J. Tubulogenesis from isolated single cells of adult mammalian kidney: clonal analysis with a recombinant retrovirus. Am J Physiol. 271:1996;F42-F49
49. Nikolovski J., Gulari E., Humes H.D. Design engineering of a bioartificial renal tubule cell therapy device. Cell Transplant. 8:1999;351-364
50. MacKay S.M., Funke A.J., Buffington D.A., Humes H.D. Tissue engineering of a bioartificial renal tubule. ASAIO J. 44:1998;179-183
51. Humes H.D., MacKay S.M., Funke A.J., Buffington D.A. Tissue engineering of a bioartificial renal tubule assist device: in vitro transport and metabolic characteristics. Kidney Int. 55:1999;2502-2514
52. Fissell W.H., Dyke D.B., Buffington D.A., et al. Bioartificial kidney alters cytokine response and hemodynamics in endotoxin challenged dogs. Blood Purif. 20:2002;55-60
53. Humes H.D., Fissell W.H., Weitzel W.F., et al. Metabolic replacement of renal function in uremic animals with a bioartificial kidney containing human cells. Am J Kidney Dis. 39:(5):2002;1078-1087
54. Humes H.D., MacKay S.M., Funke A.J., Buffington D.A. Acute renal failure: growth factors, cell therapy, gene therapy. Proc Assoc Am Physicians. 109:1997;547-557
55. Bone R.C., Grodzin C.J., Balk R.A. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 112:1997;235-243
56. Tran D.D., Groenveld A.J., van der Meulen J., et al. Age, chronic disease, sepsis, organ system failure, and mortality. Crit Care Med. 18:1990;474-479
57. Donnelly S., Robertson C. Mediators, mechanisms and mortality in major trauma. Resuscitation. 28:1994;87-92
58. Horn K. Evolving strategies in the treatment of sepsis and systemic inflammatory response syndrome (SIRS). QJM. 91:1998;265-277
59. Pinsky M.R., Vincent J.L., Deviere J., Alegre M., Khan R.J., Dupont E. Serum cytokine levels in human septic shock. Chest. 103:1993;565-575
60. Marty C., Misset B., Tamion F., Fitting C., Carlet J., Cavallion J.M. Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and non-septic origin. Crit Care Med. 22:1994;673-679
61. Sarnak M., Jaber B. Mortality caused by sepsis in patients with end-stage renal disease compared to the general population. Kidney Int. 58:2000;1758-1764
62. Girndt M., Kohler H., Schiedhelm-Weick E. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int. 47:1995;559-565
63. Girndt M., Sester U., Sester M., Kaul H., Kohler H. Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant. 14:1999;2807-2810
64. Thomas M., Lloyd-Jones D., Thadhani R., et al. Hypovitaminosis in medical inpatients. N Engl J Med. 338:1998;777-783
65. Humes H.D., Buffington D.A., Lou L., et al. Cell therapy with a tissue-engineered kidney protects against the multi-organ consequences of septic shock. Crit Care Med. 31:2003;2421-2428
66. Humes H.D., Weitzel W.F., Bartlett R.H., Swaniker F.C., Pananini E.P. Renal cell therapy is associated with dynamic and individualized responses in patients with acute renal failure. Blood Purif. 21:2003;64-71